However, locoregional recurrences still occur, making risk stratification by risk of recurrence important to guide management recommendations.1–3 The American Thyroid Association (ATA) guidelines categorize well-differentiated thyroid cancer as high, intermediate, and low risk for recurrence based on a multitude of clinical features as well as the mutation status of BRAF and TERT.4 Molecular profiling has refined the identification and prognostication of pathologic subtypes in other cancers, but is limited in papillary thyroid cancer. Here, BRAF is linked to thyroid gland papillary carcinoma.